Info

Welgen, Inc. was founded in 2002 to provide the fastest, most reliable technology available for the construction of recombinant adenoviruses and other research tools. We are currently located in a facility managed by the Massachusetts Biomedical Initiative to foster the development of new biotechnology companies in Massachusetts. We are located in Worcester, the second largest city in New England, and only a 40 min drive from Boston. Welgen offers an improved technology to simplify and accelerate the construction of adenoviral vectors, which offer many advantages to investigators who study gene expression or gene silencing in mammalian systems. Adenoviruses have a strong safety record and recombinant adenoviral vectors have been useful tools for gene function studies as well as for human gene therapy. Recombinant adenoviruses that cannot replicate are attractive vectors for gene delivery for several reasons:they infect many types of mammalian cells with high efficiency they do not disrupt the genome of the host cell but remain in the nucleus as episomal DNA they provide transient, high level gene expression they are suitable for both in vitro and in vivo applications Welgen uses the SpeAd?system to construct adenovirus vectors. The following features distinguish it from other systems: requires only standard cloning procedures such as ligation, transfection, and minipreps does not utilize homologous recombination newly constructed adenoviruses do not need to be plaque purified no special bacterial host or production cells are required dual antibiotic selection plus selective packaging ensure production of the desired vector the procedure is highly efficient and works with all HEK293 cell lines © 2004 Welgen, Inc.